🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.2810
+0.0681 (31.99%)
Nov 20, 2026, 10:12 AM EST - Market open

LABT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Selling, General & Admin
5.292.511.923.1
Research & Development
1.61.262.15.53
Operating Expenses
6.93.774.038.64
Operating Income
-6.9-3.77-4.03-8.64
Interest Expense
-0.09-0.1-0.01-0.01
Interest & Investment Income
0.070.030.140.36
Other Non Operating Income (Expenses)
0-0.080
EBT Excluding Unusual Items
-6.91-3.85-3.81-8.28
Gain (Loss) on Sale of Investments
---0-
Other Unusual Items
---1.04-
Pretax Income
-6.91-3.85-4.86-8.28
Net Income
-6.91-3.85-4.86-8.28
Preferred Dividends & Other Adjustments
1.1222-
Net Income to Common
-8.04-5.85-6.86-8.28
Net Income Growth
----
Shares Outstanding (Basic)
1111
Shares Outstanding (Diluted)
1111
Shares Change
87.70%0.78%1.44%-
EPS (Basic)
-6.16-8.40-9.92-12.16
EPS (Diluted)
-6.16-8.40-9.92-12.16
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-4.14-1.94-5.73-6.82
Free Cash Flow Per Share
-3.17-2.79-8.29-10.01
EBITDA
-6.89-3.77-4.02-8.63
D&A For EBITDA
000.010.01
EBIT
-6.9-3.77-4.03-8.64
SEC Filings: 10-K · 10-Q